120 related articles for article (PubMed ID: 23661524)
1. Significance of relaxin-2 expression in hepatocellular carcinoma: relation with clinicopathological parameters.
Pan HZ; Dong AB; Wang L; Tan SS; Yang Q; Tong XY; Liang J; Wang JR
Eur Rev Med Pharmacol Sci; 2013 Apr; 17(8):1095-101. PubMed ID: 23661524
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma.
Guo X; Yang M; Gu H; Zhao J; Zou L
Cancer Epidemiol; 2013 Oct; 37(5):732-6. PubMed ID: 23731550
[TBL] [Abstract][Full Text] [Related]
3. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma.
Yu L; Zhang J; Guo X; Li Z; Zhang P
Cancer Epidemiol; 2014 Aug; 38(4):408-13. PubMed ID: 24923856
[TBL] [Abstract][Full Text] [Related]
5. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic significance of vascular endothelial growth factor receptor 1 in hepatocellular carcinoma.
Li T; Zhu Y; Qin CY; Yang Z; Fang A; Xu S; Ren W
J Clin Pathol; 2012 Sep; 65(9):808-14. PubMed ID: 22734007
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection.
Wu H; Chen P; Liao R; Li YW; Yi Y; Wang JX; Sun TW; Zhou J; Shi YH; Yang XR; Jin JJ; Cheng YF; Fan J; Qiu SJ
J Gastroenterol Hepatol; 2012 Aug; 27(8):1312-9. PubMed ID: 22432916
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection.
Chen RX; Xia YH; Cui JF; Xue TC; Ye SL
J Gastroenterol Hepatol; 2010 Aug; 25(8):1435-42. PubMed ID: 20659235
[TBL] [Abstract][Full Text] [Related]
9. The beta2-adrenergic receptor is a potential prognostic biomarker for human hepatocellular carcinoma after curative resection.
Chen D; Xing W; Hong J; Wang M; Huang Y; Zhu C; Yuan Y; Zeng W
Ann Surg Oncol; 2012 Oct; 19(11):3556-65. PubMed ID: 22588469
[TBL] [Abstract][Full Text] [Related]
10. ASPM is a novel marker for vascular invasion, early recurrence, and poor prognosis of hepatocellular carcinoma.
Lin SY; Pan HW; Liu SH; Jeng YM; Hu FC; Peng SY; Lai PL; Hsu HC
Clin Cancer Res; 2008 Aug; 14(15):4814-20. PubMed ID: 18676753
[TBL] [Abstract][Full Text] [Related]
11. Neural cadherin overexpression is a predictive marker for early postoperative recurrence in hepatocellular carcinoma patients.
Seo DD; Lee HC; Kim HJ; Min HJ; Kim KM; Lim YS; Chung YH; Lee YS; Suh DJ; Yu E; Chun SY
J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1112-8. PubMed ID: 17944884
[TBL] [Abstract][Full Text] [Related]
12. Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma.
Mathai AM; Kapadia MJ; Alexander J; Kernochan LE; Swanson PE; Yeh MM
Am J Surg Pathol; 2012 Jul; 36(7):980-6. PubMed ID: 22446942
[TBL] [Abstract][Full Text] [Related]
13. NEMO expression in human hepatocellular carcinoma and its association with clinical outcome.
Aigelsreiter A; Haybaeck J; Schauer S; Kiesslich T; Bettermann K; Griessbacher A; Stojakovic T; Bauernhofer T; Samonigg H; Kornprat P; Lackner C; Pichler M
Hum Pathol; 2012 Jul; 43(7):1012-9. PubMed ID: 22176836
[TBL] [Abstract][Full Text] [Related]
14. Serum and tissue vascular endothelial growth factor predicts prognosis in hepatocellular carcinoma patients after partial liver resection.
Zhong C; Wei W; Su XK; Li HD; Xu FB; Guo RP
Hepatogastroenterology; 2012; 59(113):93-7. PubMed ID: 22251524
[TBL] [Abstract][Full Text] [Related]
15. Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma.
Guo X; Xiong L; Sun T; Peng R; Zou L; Zhu H; Zhang J; Li H; Zhao J
Diagn Pathol; 2012 Apr; 7():44. PubMed ID: 22515642
[TBL] [Abstract][Full Text] [Related]
16. Expression of FOXJ1 in hepatocellular carcinoma: correlation with patients' prognosis and tumor cell proliferation.
Chen HW; Huang XD; Li HC; He S; Ni RZ; Chen CH; Peng C; Wu G; Wang GH; Wang YY; Zhao YH; Zhang YX; Shen AG; Wang HM
Mol Carcinog; 2013 Aug; 52(8):647-59. PubMed ID: 22488567
[TBL] [Abstract][Full Text] [Related]
17. L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival.
Guo X; Xiong L; Zou L; Sun T; Zhang J; Li H; Peng R; Zhao J
Diagn Pathol; 2012 Aug; 7():96. PubMed ID: 22888955
[TBL] [Abstract][Full Text] [Related]
18. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification.
Zhang Y; Fan Y; Mei Z
Cancer Epidemiol; 2012 Oct; 36(5):e294-9. PubMed ID: 22728279
[TBL] [Abstract][Full Text] [Related]
19. Aberrant expression of the glycolytic enzymes aldolase B and type II hexokinase in hepatocellular carcinoma are predictive markers for advanced stage, early recurrence and poor prognosis.
Peng SY; Lai PL; Pan HW; Hsiao LP; Hsu HC
Oncol Rep; 2008 Apr; 19(4):1045-53. PubMed ID: 18357395
[TBL] [Abstract][Full Text] [Related]
20. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
